Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsFRA:QDI -1.13%79 Equity-to-Asset is 0.44 as of Jun. 2026, which is 4% below its 10-year median of 0.46. GuruFocus rates FRA:QDI with a GF Score™ of 79/100 and a GF Value™ of €166.70 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Quest Diagnostics ranks worse than 70% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Quest Diagnostics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €6,524 Mil. Quest Diagnostics's Total Assets for the quarter that ended in Jun. 2026 was €14,703 Mil.
Therefore, Quest Diagnostics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.44.
The historical rank and industry rank for Quest Diagnostics's Equity-to-Asset or its related term are showing as below:
FRA:QDI'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42 Med: 0.46 Max: 0.49
Current: 0.44
During the past 13 years, the highest Equity to Asset Ratio of Quest Diagnostics was 0.49. The lowest was 0.42. And the median was 0.46.
FRA:QDI's Equity-to-Asset is ranked worse than 70% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs FRA:QDI: 0.44
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Quest Diagnostics Equity-to-Asset Related Terms
Quest Diagnostics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:QDI vs LH, MTD, ILMN: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Quest Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Quest Diagnostics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (FRA:QDI) has a Equity-to-Asset of 0.44 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Quest Diagnostics and its competitors. This is near median its historical median of 0.46. Over the past decade, Quest Diagnostics' Equity-to-Asset has ranged from 0.42 to 0.49. According to the industry distribution chart, Quest Diagnostics ranks #147 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 70%.
Is Quest Diagnostics' Equity-to-Asset too high?
Quest Diagnostics' current Equity-to-Asset of 0.44 is near median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 0.49. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Quest Diagnostics' value of 0.44 is 25.4% below this industry median. Based on the distribution chart, Quest Diagnostics ranks #147 out of 210 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Quest Diagnostics has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Equity-to-Asset compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #147 out of 210 companies for Equity-to-Asset. This places Quest Diagnostics in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Quest Diagnostics' value of 0.44 is 25.4% below this benchmark. Historically, Quest Diagnostics' own Equity-to-Asset has ranged from 0.42 to 0.49 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.59, Quest Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Diagnostics's current Equity-to-Asset of 0.44 is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Quest Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Diagnostics's current Equity-to-Asset is 0.44, which is near median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (FRA:QDI) is currently considered Modestly Overvalued. The stock's GF Value™ is €166.70, compared to a current price of €201.30 — trading 20.8% above its estimated fair value. The current Equity-to-Asset is 0.44, which is near median its 10-year median of 0.46 and 25.4% below the Medical Diagnostics & Research industry median of 0.59. Quest Diagnostics' overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Quest Diagnostics (FRA:QDI), the current Equity-to-Asset is 0.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (FRA:QDI) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €201.30 is trading 20.8% above its estimated GF Value™ of €166.70.
GuruFocus considers Quest Diagnostics to be Modestly Overvalued.
Key valuation signals for FRA:QDI:
Equity-to-Asset: 0.44 (near median its 10-year median of 0.46)
GF Value™: €166.70 vs. price of €201.30 (20.8% above fair value)
Industry Position: 25.4% below the Medical Diagnostics & Research median (#147 of 210)
No single metric tells the full story. See the FRA:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
79GF Score
Get the complete analysis for FRA:QDI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QDI has been successfully added to your 
